{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T19:36:05Z","timestamp":1720553765750},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1053\/j.seminoncol.2003.12.002","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T13:58:14Z","timestamp":1131026294000},"page":"2-6","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S2","title":["Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma"],"prefix":"10.1053","volume":"31","author":[{"given":"Neil L","family":"Berinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Mangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2003.12.002_BIB1","first-page":"3909","article-title":"The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"abstr","key":"10.1053\/j.seminoncol.2003.12.002_BIB2","first-page":"674a","article-title":"Clinical characteristics and response to chemotherapy of mantle cell lymphomas\u2013Results of a European survey","volume":"88","author":"Hiddemann","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB5","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma","volume":"10","author":"Haas","year":"1996","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1701046","article-title":"High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin\u2019s lymphomas","volume":"21","author":"Blay","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB7","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"H-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1083-8791(00)70030-9","article-title":"Autologous hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"6","author":"Vose","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB9","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2003.50025","article-title":"The mechanisms of action of rituximab in the elimination of tumor cells","volume":"30","author":"Johnson","year":"2003","journal-title":"Semin Oncol"},{"issue":"abstr","key":"10.1053\/j.seminoncol.2003.12.002_BIB13","first-page":"8","article-title":"Mantle cell lymphoma (MCL)\u2013Update on results after R-HCVAD without stem cell transplant (SCT)","volume":"13","author":"Romaguera","year":"2002","journal-title":"Ann Oncol"},{"issue":"abstr","key":"10.1053\/j.seminoncol.2003.12.002_BIB14","first-page":"92a","article-title":"The addition of rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL)","volume":"100","author":"Hiddemann","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB15","first-page":"150","article-title":"Combined immunochemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma\u2013Final results of a prospective randomized trial of the GLSG","volume":"4","author":"Dreyling","year":"2002","journal-title":"Hematol"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/sonc.2003.50022","article-title":"Rituximab","volume":"30","author":"Gisselbrecht","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2003.12.002_BIB18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775403006407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775403006407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:03:09Z","timestamp":1586538189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775403006407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":18,"alternative-id":["S0093775403006407"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2003.12.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}